Basic Information
| LncRNA/CircRNA Name | DRHC |
| Synonyms | DHRC,?DRHC, HUMORF5 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi, Western blot, other |
| Sample | HCC tissues and cell lines (Huh-7 and SK-Hep-1) |
| Expression Pattern | down-regulated |
| Function Description | Gain-of-function studies indicated that it inhibited proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in HCC cell lines in vitro. lncRNA DRHC also inhibited tumorigenicity in vivo. In mechanistic experiments, GO analysis based on NGS indicated that MAPK signaling was most affected. The result was confirmed by Western blot and this effect was abolished either by MEK1/2 specific inhibitor Trametinib or ERK1/2 inhibitor SCH772984. In addition, differences in proliferation and invasion were abrogated by Trametinib. Moreover, we found that lncRNA DRHC interacted with MYBBP1A and modulated MEK/ERK signaling via c-Myb. |
| Pubmed ID | 30362626 |
| Year | 2019 |
| Title | lncRNA DRHC Inhibits Proliferation and Invasion in Hepatocellular Carcinoma via c-Myb-regulated MEK/ERK Signaling |
External Links
| Links for DRHC | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |